ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company,
announced today that a conference call to discuss fourth quarter and
year end 2008 results will be held on Thursday, March 26, 2009 at 8:00
a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In (Toll Free): 877-874-1589
Dial In (International): 719-325-4805
Passcode (if requested): 6454631
Preregistration is not required. This call is also being webcast and can
be accessed at ARYx Therapeutics’ web site at www.aryx.com.
Replays of the call will be available through May 1, 2009 at the ARYx
web site.
About ARYx Therapeutics, Inc.
ARYx Therapeutics is a biopharmaceutical company focused on developing a
portfolio of internally discovered products designed to eliminate known
safety issues associated with well-established, commercially successful
drugs. ARYx uses its RetroMetabolic Drug Design technology to design
structurally unique molecules that retain the efficacy of these original
drugs but are metabolized through a potentially safer pathway to avoid
specific adverse side effects associated with these compounds. ARYx
currently has four products in clinical trials: an oral anticoagulant
agent for patients at risk for the formation of dangerous blood clots,
tecarfarin (previously ATI-5923); an oral anti-arrhythmic agent for the
treatment of atrial fibrillation, budiodarone (previously ATI-2042); a
prokinetic agent for the treatment of various gastrointestinal
disorders, ATI-7505; and, an agent for the treatment of schizophrenia
and other psychiatric disorders, ATI-9242. Please visit our web site at www.aryx.com
for additional information.
ARYx Therapeutics, Inc.
David Nagler, 510-585-2200 x 211
